Further supporting our findings, a similar poor prognosis has previously been described for patients with EZH2 mutations and the related myeloid malignancies MPN and MDS (Guglielmelli et al., 2011; Bejar et al., 2012), and recent efforts to refine prognostic groups within AML (Papaemmanuil et al., 2016) have identified the chromatin and spliceosome group, in which EZH2 mutations are grouped, as one of the groups with the poorest survival. This evidence concerns the gene EZH2 and myeloid neoplasm.